Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 788

1.

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.

Guillén Y, Noguera-Julian M, Rivera J, Casadellà M, Zevin AS, Rocafort M, Parera M, Rodríguez C, Arumí M, Carrillo J, Mothe B, Estany C, Coll J, Bravo I, Herrero C, Saz J, Sirera G, Torrella A, Navarro J, Crespo M, Negredo E, Brander C, Blanco J, Calle ML, Klatt NR, Clotet B, Paredes R.

Mucosal Immunol. 2018 Aug 31. doi: 10.1038/s41385-018-0083-7. [Epub ahead of print]

PMID:
30171206
2.

Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up.

Videla S, Tarrats A, Ornelas A, Badia R, Castella E, Alcalde C, Chamorro A, Esté JA, Clotet B, Sirera G.

Int J STD AIDS. 2018 Aug 31:956462418792653. doi: 10.1177/0956462418792653. [Epub ahead of print]

PMID:
30170532
3.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.

Pelchen-Matthews A, Ryom L, Borges ÁH, Edwards S, Duvivier C, Stephan C, Sambatakou H, Maciejewska K, Portu JJ, Weber J, Degen O, Calmy A, Reikvam DH, Jevtovic D, Wiese L, Smidt J, Smiatacz T, Hassoun G, Kuznetsova A, Clotet B, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001967. [Epub ahead of print]

PMID:
30134296
4.

High Prevalence of Sarcopenia in HIV-Infected Individuals.

Echeverría P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E.

Biomed Res Int. 2018 Jul 12;2018:5074923. doi: 10.1155/2018/5074923. eCollection 2018.

5.

Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men.

Vela S, Videla S, Ornelas A, Revollo B, Clotet B, Sirera G, Piñol M, García-Cuyás F.

PLoS One. 2018 Aug 1;13(8):e0199033. doi: 10.1371/journal.pone.0199033. eCollection 2018.

6.

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm.

Vamvaka E, Farré G, Molinos-Albert LM, Evans A, Canela-Xandri A, Twyman RM, Carrillo J, Ordóñez RA, Shattock RJ, O'Keefe BR, Clotet B, Blanco J, Khush GS, Christou P, Capell T.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7854-E7862. doi: 10.1073/pnas.1806022115. Epub 2018 Jul 30.

7.

CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir.

Badia R, Ballana E, Castellví M, García-Vidal E, Pujantell M, Clotet B, Prado JG, Puig J, Martínez MA, Riveira-Muñoz E, Esté JA.

Nat Commun. 2018 Jul 16;9(1):2739. doi: 10.1038/s41467-018-05157-w.

8.

ADAR1 affects HCV infection by modulating innate immune response.

Pujantell M, Franco S, Galván-Femenía I, Badia R, Castellví M, Garcia-Vidal E, Clotet B, de Cid R, Tural C, Martínez MA, Riveira-Muñoz E, Esté JA, Ballana E.

Antiviral Res. 2018 Aug;156:116-127. doi: 10.1016/j.antiviral.2018.05.012. Epub 2018 Jun 12.

PMID:
29906476
9.

High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs.

Negredo E, Langohr K, Bonjoch A, Pérez-Alvárez N, Estany C, Puig J, Rosales J, Echeverría P, Clotet B, Gómez G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2452-2459. doi: 10.1093/jac/dky201.

PMID:
29860519
10.

Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.

Negredo E, Clotet B.

Expert Opin Pharmacother. 2018 Jun;19(8):929-934. doi: 10.1080/14656566.2018.1472766. Epub 2018 May 16.

PMID:
29767543
11.

Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Bravo I, Álvarez H, Mariño A, Clotet B, Moltó J.

Br J Clin Pharmacol. 2018 Jul;84(7):1617-1619. doi: 10.1111/bcp.13583. Epub 2018 Apr 16. No abstract available.

PMID:
29663482
12.

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.

Puertas MC, Gómez-Mora E, Santos JR, Moltó J, Urrea V, Morón-López S, Hernández-Rodríguez A, Marfil S, Martínez-Bonet M, Matas L, Muñoz-Fernández MA, Clotet B, Blanco J, Martinez-Picado J.

J Antimicrob Chemother. 2018 Apr 4. doi: 10.1093/jac/dky106. [Epub ahead of print]

13.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.

Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, Clotet B, Gatell JM, de Lazzari E, Martinez E; DOLAM Study Team .

J Antimicrob Chemother. 2018 Mar 28. doi: 10.1093/jac/dky093. [Epub ahead of print]

PMID:
29608685
14.

Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.

Salgado M, Garcia-Minambres A, Dalmau J, Jiménez-Moyano E, Viciana P, Alejos B, Clotet B, Prado JG, Martinez-Picado J.

J Virol. 2018 May 29;92(12). pii: e00346-18. doi: 10.1128/JVI.00346-18. Print 2018 Jun 15.

15.

Early diagnosis of HIV infection among men who have sex with men in Lima (Peru). A prospective cohort study.

Coll J, Videla S, Ganoza C, Ornelas A, Pérez S, Clotet B, Brander C, Sánchez J.

Clin Microbiol Infect. 2018 Jul;24(7):793-795. doi: 10.1016/j.cmi.2018.02.029. Epub 2018 Mar 2. No abstract available.

PMID:
29505882
16.

Aging in HIV-Infected Subjects: A New Scenario and a New View.

Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, Guaraldi G, Mallon P, Moltó J, Serra JA, Clotet B.

Biomed Res Int. 2017;2017:5897298. doi: 10.1155/2017/5897298. Epub 2017 Dec 21. Review.

17.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
18.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Moltó J, Curran A, Miranda C, Challenger E, Santos JR, Ribera E, Khoo S, Valle M, Clotet B.

J Antimicrob Chemother. 2017 Dec 11. doi: 10.1093/jac/dkx459. [Epub ahead of print]

PMID:
29237008
19.

Memory B cell dysregulation in HIV-1-infected individuals.

Carrillo J, Negredo E, Puig J, Molinos-Albert LM, Rodríguez de la Concepción ML, Curriu M, Massanella M, Navarro J, Crespo M, Viñets E, Millá F, Clotet B, Blanco J.

AIDS. 2018 Jan 14;32(2):149-160. doi: 10.1097/QAD.0000000000001686.

PMID:
29112067
20.

RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages.

Pujantell M, Riveira-Muñoz E, Badia R, Castellví M, Garcia-Vidal E, Sirera G, Puig T, Ramirez C, Clotet B, Esté JA, Ballana E.

Sci Rep. 2017 Oct 17;7(1):13339. doi: 10.1038/s41598-017-13580-0.

21.

Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Molinos-Albert LM, Clotet B, Blanco J, Carrillo J.

Front Immunol. 2017 Sep 19;8:1154. doi: 10.3389/fimmu.2017.01154. eCollection 2017. Review.

22.

Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan area of Barcelona, 2002-2016).

Roure S, Valerio L, Pérez-Quílez O, Fernández-Rivas G, Martínez-Cuevas O, Alcántara-Román A, Viasus D, Pedro-Botet ML, Sabrià M, Clotet B.

PLoS One. 2017 Sep 27;12(9):e0185245. doi: 10.1371/journal.pone.0185245. eCollection 2017.

23.

Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery.

Gómez-Mora E, Massanella M, García E, Giles D, Bernadó M, Urrea V, Carrillo J, Ouchi D, Puig J, Negredo E, Clotet B, Blanco J, Cabrera C.

PLoS One. 2017 Sep 21;12(9):e0184433. doi: 10.1371/journal.pone.0184433. eCollection 2017.

24.

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery.

Gómez-Mora E, García E, Urrea V, Massanella M, Puig J, Negredo E, Clotet B, Blanco J, Cabrera C.

Sci Rep. 2017 Sep 15;7(1):11711. doi: 10.1038/s41598-017-12013-2.

25.

Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals.

Juega-Mariño J, Bonjoch A, Pérez-Alvarez N, Negredo E, Bayes B, Bonet J, Clotet B, Romero R.

Medicine (Baltimore). 2017 Sep;96(37):e7421. doi: 10.1097/MD.0000000000007421.

26.

Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir.

Garcia-Vidal E, Castellví M, Pujantell M, Badia R, Jou A, Gomez L, Puig T, Clotet B, Ballana E, Riveira-Muñoz E, Esté JA.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01368-17. doi: 10.1128/AAC.01368-17. Print 2017 Nov.

27.

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.

Muñoz-Moreno JA, Prats A, Moltó J, Garolera M, Pérez-Álvarez N, Díez-Quevedo C, Miranda C, Fumaz CR, Ferrer MJ, Clotet B; TRIANT-TE Study Group.

PLoS One. 2017 Aug 30;12(8):e0182547. doi: 10.1371/journal.pone.0182547. eCollection 2017.

28.

Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men.

Coll J, Videla S, Leon A, Ornelas A, García F, Fernández E, Blanco JL, Carrillo A, Bravo I, Meulbroek M, García-Cuyas F, González V, Casabona J, Leal L, Clotet B, Brander C; Check-Ear Project.

Clin Microbiol Infect. 2018 May;24(5):540-545. doi: 10.1016/j.cmi.2017.08.012. Epub 2017 Aug 24.

PMID:
28843621
29.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR.

Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.

PMID:
28750935
30.

Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV-Coinfected Patients in Clinical Practice.

López JJ, Pérez-Àlvarez N, Rodríguez RV, Jou A, Carbonell P, Jiménez JA, Soldevila L, Tenesa M, Tor J, Clotet B, Bechini J, Tural C.

J Ultrasound Med. 2018 Jan;37(1):113-121. doi: 10.1002/jum.14312. Epub 2017 Jul 17.

PMID:
28715086
31.

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.

Echeverría P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E.

HIV Med. 2017 Nov;18(10):782-786. doi: 10.1111/hiv.12530. Epub 2017 Jul 3.

PMID:
28671337
32.

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.

Codoñer FM, Peña R, Blanch-Lombarte O, Jimenez-Moyano E, Pino M, Vollbrecht T, Clotet B, Martinez-Picado J, Draenert R, Prado JG.

Sci Rep. 2017 Jun 16;7(1):3717. doi: 10.1038/s41598-017-03260-4.

33.

Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals.

Echeverría P, Gómez-Mora E, Roura S, Bonjoch A, Puig J, Pérez-Alvarez N, Bayés-Genís A, Clotet B, Blanco J, Negredo E.

J Antimicrob Chemother. 2017 Jul 1;72(7):2049-2054. doi: 10.1093/jac/dkx074.

PMID:
28369542
34.

SAMHD1 is active in cycling cells permissive to HIV-1 infection.

Badia R, Pujantell M, Torres-Torronteras J, Menéndez-Arias L, Martí R, Ruzo A, Pauls E, Clotet B, Ballana E, Esté JA, Riveira-Muñoz E.

Antiviral Res. 2017 Jun;142:123-135. doi: 10.1016/j.antiviral.2017.03.019. Epub 2017 Mar 28.

PMID:
28359840
35.

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Sedlacek D, Zilmer K, Clotet B, Lundgren JD, Paredes R; EuroSIDA in EuroCOORD.

PLoS One. 2017 Jan 27;12(1):e0166613. doi: 10.1371/journal.pone.0166613. eCollection 2017.

36.

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Molinos-Albert LM, Bilbao E, Agulló L, Marfil S, García E, Rodríguez de la Concepción ML, Izquierdo-Useros N, Vilaplana C, Nieto-Garai JA, Contreras FX, Floor M, Cardona PJ, Martinez-Picado J, Clotet B, Villà-Freixa J, Lorizate M, Carrillo J, Blanco J.

Sci Rep. 2017 Jan 13;7:40800. doi: 10.1038/srep40800.

37.

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.

Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, Negredo E.

Biomed Res Int. 2016;2016:4380845. doi: 10.1155/2016/4380845. Epub 2016 Dec 18.

38.

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.

Negredo E, Estrada V, Domingo P, Gutiérrez MD, Mateo GM, Puig J, Bonjoch A, Ornelas A, Echeverría P, Estany C, Toro J, Clotet B.

J Antimicrob Chemother. 2017 Mar 1;72(3):844-849. doi: 10.1093/jac/dkw504.

PMID:
27999056
39.

Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.

Moltó J, Rajoli R, Back D, Valle M, Miranda C, Owen A, Clotet B, Siccardi M.

J Antimicrob Chemother. 2017 Mar 1;72(3):805-811. doi: 10.1093/jac/dkw485.

PMID:
27999009
40.

Brief Report: Impaired CD4 T-Cell Response to Autophagy in Treated HIV-1-Infected Individuals.

Gómez-Mora E, Robert-Hebmann V, García E, Massanella M, Clotet B, Cabrera C, Blanco J, Biard-Piechaczyk M.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):201-205. doi: 10.1097/QAI.0000000000001201.

PMID:
27787338
41.

Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men.

Fumaz CR, Ayestaran A, Perez-Alvarez N, Muñoz-Moreno JA, Ferrer MJ, Negredo E, Clotet B.

Am J Mens Health. 2017 May;11(3):647-653. doi: 10.1177/1557988316669041. Epub 2016 Sep 19.

42.

Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components.

Llibre JM, de Lazzari E, Molina JM, Gallien S, Gonzalez-García J, Imaz A, Podzamczer D, Clotet B, Domingo P, Gatell JM.

Enferm Infecc Microbiol Clin. 2018 Jan;36(1):16-20. doi: 10.1016/j.eimc.2016.07.006. Epub 2016 Aug 29. English, Spanish.

PMID:
27595183
43.

The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells.

Badia R, Pujantell M, Riveira-Muñoz E, Puig T, Torres-Torronteras J, Martí R, Clotet B, Ampudia RM, Vives-Pi M, Esté JA, Ballana E.

PLoS Pathog. 2016 Aug 19;12(8):e1005829. doi: 10.1371/journal.ppat.1005829. eCollection 2016 Aug.

44.

Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.

Bonjoch A, Puig J, Pérez-Alvarez N, Juega J, Echeverría P, Clotet B, Romero R, Bonet J, Negredo E.

Medicine (Baltimore). 2016 Aug;95(32):e4507. doi: 10.1097/MD.0000000000004507.

45.

Long-term HIV-1 infection induces an antiviral state in primary macrophages.

Pujantell M, Badia R, Ramirez C, Puig T, Clotet B, Ballana E, Esté JA, Riveira-Muñoz E.

Antiviral Res. 2016 Sep;133:145-55. doi: 10.1016/j.antiviral.2016.08.004. Epub 2016 Aug 7.

PMID:
27510577
46.

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzon MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J.

Retrovirology. 2016 Aug 2;13(1):51. doi: 10.1186/s12977-016-0282-9.

47.

Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.

Moltó J, Estévez JA, Miranda C, Cedeño S, Clotet B, Valle M.

Br J Clin Pharmacol. 2016 Dec;82(6):1528-1538. doi: 10.1111/bcp.13072. Epub 2016 Sep 13.

48.

Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.

Jimenez-Moyano E, Ruiz A, Kløverpris HN, Rodriguez-Plata MT, Peña R, Blondeau C, Selwood DL, Izquierdo-Useros N, Moris A, Clotet B, Goulder P, Towers GJ, Prado JG.

J Virol. 2016 Sep 12;90(19):8552-62. doi: 10.1128/JVI.00819-16. Print 2016 Oct 1.

49.

Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes.

Pérez-Santiago J, Ouchi D, Urrea V, Carrillo J, Cabrera C, Villà-Freixa J, Puig J, Paredes R, Negredo E, Clotet B, Massanella M, Blanco J.

AIDS. 2016 Sep 24;30(15):2275-87. doi: 10.1097/QAD.0000000000001205.

50.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. Erratum in: JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185

Supplemental Content

Loading ...
Support Center